APPENDIX 1 Eight New Cases of LAHS and Review of the Literature: Clinical and Laboratory Data

Similar documents
APPENDIX 2 Eight New Cases of LAHS and Review of Literature: Treatment and Follow-Up

Manifestation of Antiphospholipid Syndrome among Saudi patients :examining the applicability of sapporo Criteria

Pediatric Bleeding Questionnaire (PBQ)

Are there still any valid indications for thrombophilia screening in DVT?

The Antiphospholipid Syndrome

Lupus anticoagulant-hypoprothrombinemia syndrome: report of two cases and review of the literature

UKITP INITAL INFORMATION SHEET (2.4)

Recommendations for Celiac Disease Testing. IgA & ttg IgA

Key words: antiphospholipid syndrome, trombosis, pathogenesis

Antiphospholipid Antibody Syndrome: Management Issues for the Hematologist

Thrombophilia. Dr. A Sarrafnejad PhD Dep. Immunology School of public health TUMS

Bleeding Disorders. Dr. Mazen Fawzi Done by Saja M. Al-Neaumy Noor A Mohammad Noor A Joseph Joseph

BLEEDING DISORDERS Simple complement:

HENOCH SCHÖNLEIN PURPURA (VASCULAR PURPURA, ANAPHYLACTOID PURPURA) IN CHILDREN Single choice tests (SC)

Lupus Anticoagulants (LA), Antiphospholipid (APL) Antibodies & APL Syndrome: Review & Update. Antiphospholipid. Antiphospholipid

Antiphospholipid Syndrome

Antiphospholipid Syndrome ( APS)

Pathophysiology. Tutorial 3 Hemodynamic Disorders

Anti β 2. -Glycoprotein I and Antiphosphatidylserine Antibodies Are Predictors of Arterial Thrombosis in Patients With Antiphospholipid Syndrome

Current View of the Treatment of Antiphospholipid Syndrome

ANTIPHOSPHOLIPID (HUGHES) SYNDROME

There are two main causes of a low platelet count

Generate Knowledge Lupus Anticoagulant Testing Made Simple

Anticoagulants and Head Injuries. Asaad Shujaa,MD,FRCPC,FAAEM Assistant Professor,weill Corneal Medicne Senior Consultant,HMC Qatar

Testing strategies for diagnosing lupus anticoagulant: decision analysis Segal J B, Lehmann H P, Petri M, Mueller L, Kickler T S

Clinical & Laboratory Assessment

Dr. Rai Muhammad Asghar Associate Professor Head of Pediatric Department Rawalpindi Medical College

Form 2033 R3.0: Wiskott-Aldrich Syndrome Pre-HSCT Data

What is the appropriate evaluation of cryptogenic stroke, and when is a hypercoagulability work-up needed? David E. Thaler, MD, PhD, FAHA

V.N. KARAZIN KHARKOV NATIONAL UNIVERSITY

Mortality in the Catastrophic Antiphospholipid Syndrome

Case Report Lower Limb Ischemia: Aortoiliac Thrombosis Related to Antiphospholipid Syndrome (APS) Case Report and Review of the Literature

Bleeding Disorders.2 MS Abdallah Awidi Abbadi.MD. FRCP.FRCPath Feras Fararjeh MD

Coagulation Disorders. Dr. Muhammad Shamim Assistant Professor, BMU

Patient with Musculo-skeletal Complaints - Summary

Mohammadreza Tabatabaei IBTO COAG LAB

HEME 10 Bleeding Disorders

DOWNLOAD OR READ : POSITIVE OPTIONS FOR ANTIPHOSPHOLIPID SYNDROME APS SELF HELP AND TREATMENT PDF EBOOK EPUB MOBI

Contemporary perspectives and initial management of pediatric ITP. William Beau Mitchell, MD Weill Cornell Medical College New York, NY USA

Thrombophilia: To test or not to test

Haemostasis & Coagulation disorders Objectives:

THE antiphospholipid-antibody syndrome is a

THROMBOSIS RISK FACTOR ASSESSMENT

TECHNICAL SERIES. Lupus Anticoagulants: Basic Concepts and Laboratory Diagnosiss. ...Setting trends TULIP DIAGNOSTICS (P) LTD.

10/24/2013. Heparin-Induced Thrombocytopenia (HIT) Anticoagulation Management in ECMO Therapy:

A Case of Massive Pulmonary Embolism in Systemic Lupus Erythematosus without Antiphospholipid Antibody

Symptomatic VWD in a Pediatric Population- a guide to administering the Bleeding Questionnaire

Transfusion Requirements and Management in Trauma RACHEL JACK

Supplementary Online Content

Guidelines for Shared Care Centres and Community Staff

AN INTERESTING CASE OF RESPIRATORY DISTRESS. Dr.V.Akila Devi DNB PG Southern Railway Headquarters Hospital Chennai

Warfarin Does Not Interfere with Lupus Anticoagulant Detection by Dilute Russell s Viper Venom Time

Online Supplementary Data. Country Number of centers Number of patients randomized

Nitroglycerin and Heparin Drip Interfacility Protocols

Anaesthesiologic management of a parturient with a known antiphospholipid syndrome

Sang Hyuk Park, 1,2 Seongsoo Jang, 3 Chan-Jeoung Park, 3 and Hyun-Sook Chi Introduction

Pulse 110/min beats per min + 20 Systolic blood pressure <100 mmhg Respiratory rate 30 breaths per min + 20

A Case of Antiphospholipid Syndrome Refractory to Secondary Anticoagulating Prophylaxis after Deep Vein Thrombosis- Pulmonary Embolism

Purpura fulminans: A rare presentation of antiphospholipid syndrome

Epidemiologia e clinica del tromboembolismo venoso. Maria Ciccone Sezione di Ematologia e Fisiopatologia della Coagulazione

Sindrome da anticorpi antifosfolipidi: clinica e terapia. Vittorio Pengo Clinical Cardiology, Padova, Italy

ACQUIRED COAGULATION ABNORMALITIES

monoclonal gammopathy of undetermin Citation Rheumatology international, 33(1),

Name and Intended Use

Available Online at CODEN: IJRSFP (USA) Vol. 9, Issue, 3(L), pp , March, 2018.

Figure 1: Consort diagram; the status of participants in the study

Hematologic Disorders. Assistant professor of anesthesia

Pediatric thrombosis: Diagnosis and Management

Bleeding disorders. Hemostatic failure: Inappropriate and excessive bleeding either spontaneous or in response to injury.

DISCLOSURE. Presented by: Merav Sendowski, MD Oregon Health and Science University

Hemostasis. PHYSIOLOGICAL BLOOD CLOTTING IN RESPONSE TO INJURY OR LEAK no disclosures

AMPLIADO SÍNDROME ANTIFOSFOLÍPIDO SÍNDROME DE SJÖGREN María José Cuadrado Lozano Clínica Universidad de Navarra-Madrid

Daniel Egan, MD April 13, 2012

Prevalence of antiphospholipid auto antibodies in patients with thrombosis

Guidelines for management of stroke in childhood

Interactive Case Vignette: DOACs (Direct Oral Anti-Coagulants) vs. Warfarin for APLA (Anti-Phospholipid Antibody Syndrome)

Medical Surgical Review Handout- Hematology/Oncology 2016

University Health System

Part 1 examination. Haematology: First paper. Tuesday 25 September 2018

COAGULATIONS. Dr. Hasan Fahmawi, MRCP(UK), FRCP(Edin)

9/25/2013 SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)

Disorders of the kidney. Urine analysis. Nephrotic and nephritic syndrome.

Supplemental Appendix. 1. Protocol Definition of Sustained Virologic Response. A patient has a sustained virologic response if:

T he antiphospholipid syndrome (APS) is a thrombophilic

PD Dr. med. habil. Michaela Jaksch, Consultant Laboratory Medicine, Medical Director, Freiburg Medical Laboratory ME LLC, Dubai, UAE

LAMA SHATAT TTP, ITP, DIC

Catastrophic antiphospholipid syndrome: A rare but serious complication of antiphospholipid antibody syndrome Sandhu VK*; Singh H

ANTIPHOSPHOLIPID ANTIBODIES IN 57 CHILDREN AND ADOLESCENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS

Antiphospholipid Syndrome Handbook

Antiphospholipid antibodies

Anticoagulation Therapy in LTC

Dr Kirsten Herbert. Dr Melita Kenealy. MBBS(Hons) FRCPA FRACP. Common Blood Tests

Reliability and Validity of PPCs in the MHAC Program

Platelet Disorders. By : Saja Al-Oran

Clinical consequences of antiphospholipid antibodies

Approach to disseminated intravascular coagulation

Appendix. Potentially Preventable Complications (PPCs) identify. complications that can occur during an admission. There are 64

Case report 24 th Summer School of Internal Medicine 2015

Antiphospholipid antibodies in patients with venous thrombosis at Kenyatta National Hospital

All about Antiphospholipid Syndrome. M.B. Agarwal, MD Prof & Head, Dept of Haematology, Bombay Hospital Institute of Medical Sciences, Mumbai, India

Transcription:

Supplementary Digital Content 1 Mazodier et al. Lupus Anticoagulant- Hypoprothrombinemia Syndrome: Report of 8 Cases and Review of the Literature Medicine (Baltimore). 2012;91(5). APPEDIX 1 Eight ew Cases of LAHS and Review of the Literature: Clinical and Laboratory Data First Author (year)/ref Sex/Age (yr) Bleeding Events Thrombotic and Obstetric Events Associated Disease aptt PT (sec) FII Level Anti- Factor II Ab apl Other Case 1/PR M/65 Intracerebral Deep venous thrombosis Primary APS 4 26.6 (1.9 ) 11% acl IgG: 366 a-β2gp1 IgG: 12 (117 g/l) Case 2/PR F/13 Case 3/PR F/56 Gum, Post-dental extraction no SLE >4 18% 4% no Lupus-like syndrome (arthritis and skin lesion) (D) acl IgG: 9 a-β2gp1: D >4 (IR 1.98) 38% acl: Case 4/PR M/43 Intramuscular (t-trauma) no 2.5 37% 20% acl IgG: 10 a-β2gp1: D Case 5/PR M/48 o Case 6/PR M/57 Case 7/PR F/50 Hematoma (tsurgery) Metrorrhagia and (tsurgery) Arterial stenosis and thrombosis 3 miscarriages (medical history) Primary APS >4 16.3 (1.3 ) 35% D no 4 46% 12% SLE, obstetric APS 3 17.1 (1.4 ) 33% Case 8/PR F/13 Metrorrhagia SLE 3.5 44% 20% Rapaport (1960)/[42] F/11 gum +++ IgG : 2 IgG : 23 acl IgG: +++ a-β2gp1 IgG: +++ acl IgG: 37 a-β2gp1: IgG+++ acl IgG: 8 acl IgM: 1.5 a-β2gp1 IgG: 2 acl IgG: 18 a-β2gp1: 66 no SLE 2 21% 10% D D 1

Perkins (1960)/[39] Biggs (1964)/[10] Gonyea (1968)/[21] Corrigan (1970)/[13] Bajaj (1983)/[6] Shaulian (1981)/[46] Follea (1981)/[19] Houbouyan (1984)/[28] Schwartz (1984)/[44] Harrison (1987)/[23] Simel (1987)/[47] Small (1988)/[48] Stormorken (1988)/[49] F/33 F/11 M/45 F/4 F/56 F/37 Menorrhagia, gum, Bleeding after tooth extraction, Hematuria, Severe Ecchymosis, major Postoperative Postoperative (hysterectomy) no Lupus-like syndrome D D 40% D D no Lupus-like syndrome D 1.5 20% D D Lupus-like syndrome D 2 10% D D no SLE D 43 (3 ) 30% D D Yes (D) SLE 1.5 31 (2 ) < 1% D D no Viral 3 35 (2.5 ) 1% D no SLE + viral 2.5 19 (1.7 ) 6% D Arterial and venous thrombosis, pulmonary embolism SLE 2 20% D D D no SLE 4 12% D D D M/39 o symptom no Lymphoma 3 D 20% D D F/2 M/14 M/42 Ecchymosis,, gum, Bleeding after tooth extraction gum no Viral 2 23.5 (1.7 ) 3% D D no SLE 1.5 16 (1.2 ) 23% D acl: no Drug 2 20 (1.6 ) 8% M/66 o symptom no no 1.5 11.9 (1.1 ) 32% D M/22 F/40 gum Metrorrhagia,, acl IgG: acl IgM: acl IgG: VDRL+/TPHA- no SLE 3 23 (1.9 ) 4% D acl: 3 miscarriages at 12 SA (medical history) SLE 3 *20% 5% D VDRL+/TPHA- (15 g/l) (86 g/l) (114 g/l) 2

Baudo (1990)/[7] Hift (1991)/[24] Jaeger (1993)/[31] Bernini (1993)/[9] Humphries (1994)/[30] Peacock (1994)/[37] Eberhard (1994)/[17] Lee (1996)/[33] Williams (1996)/[53] Côté (1997)/[14] M/23 M/24 intramuscular no SLE 2.4 D 1% no SLE 3 16 (1.6 ) 2% D D M/3 o symptom no Viral 2 34% 16% F/4 o symptom no Viral 1.7 <5% 10% F/7 o symptom no Viral 3 45% 22% F/5 o symptom no Viral 3 6% 11% F/3 F/5 M/38 F/15 F/10 F/11 Ecchymosis,, gum, gastrointestinal gastrointestinal, subdural Menorrhagia, Hematuria, bruising, petechiae Petechiae, conjunctival hemorrhage acl: no Viral 3 >100 (>3 ) <1% D acl: 2 no Viral 1.8 17.2 (1.3 ) 15% D acl: Myocardial infarction Primary APS 3 23 (1.8 ) 13% acl: 2 no SLE 3 21.5 (1.8 ) 5% D VDRL+/TPHA- Deep venous thombosis SLE, pneumococcal infection 1.5 23 (1.9 ) 12% D D no SLE 1.5 19 (1.6 ) 4% D D F/2 Bruising Viral 2 23 (1.8 ) 14% acl: M/64 tbiopsy no Discoid lupus 1.5 13.6 (1.2 ) 22% acl IgG: acl IgM: F/9 Epistaxis no Celiac disease 5 43 (3.2 ) 2% acl: (132 g/l) (115 g/l) 3

Becton (1997)/[8] Pernod (1997)/[40] Grau (1997)/[22] Vivaldi (1997)/[52] Moll (1997)/[36] Hudson (1997)/[29] Amiral (1997)/[1] de Larranaga (1999)/[16] Male (1999)/[35] Erkan (1999)/[18] F/8 M/2 bruising no no 2.5 17 (1.3 ) 17% D acl: no Viral 2.5 23 (1.8 ) 12% D acl: M/10 Elbow no Viral 1.6 16 (1.2 ) 12% D acl: M/4 Hematemesis, no Viral 2 27.5 (2.1 ) 7% D acl: M/40 Hematuria no no 2 17.5 (1.2 ) F/17 M/43 Postcutaneous biopsy hemorrhage,, bruising, metrorrhagia Subdural 0.1 UI/mL no SLE 1.5 23 (1.7 ) 30% D no SLE 3.5 2.4 5% D acl: a-β2gp1: acl IgG: 3 acl IgM: 1.2 acl IgG: acl IgM: no o 2 16.1 (1.4 ) 19% D acl IgG: F/15 Menorrhagia Amaurosis fugax Primary APS 1.5 13.4 (1.1 ) 0.27 U/mL F/6 Purpura no Adenovirus 1.6 15.5 (1.2 ) 26% M/28 melena no Pneumonia, autoimmune hepatitis 3.3 D (1.6 ) 30% D : 34 acl IgG: 3 acl IgM: 1.5 acl: a-β2gp1: acl IgG: 22 a-β2gp1 IgG: 25 a-β2gp1 IgM: 2 F/4 Purpura no Adenovirus D D 10% D F/4 Bruising no Adenovirus M/4 Melena no Adenovirus M/8 Bruising no Adenovirus M/2 Hemorrhagic diarrhea no Adenovirus D. D D D D 9% D D 18% D D 5% D D 16% D F/19 Menorrhagia no SLE 2 17.8 (1.3 ) 11% D F/47 Macroscopic acl IgG: acl IgM: no SLE 1.5 22.1 (1.7 ) 21% D acl IgG: (102 g/l) (119 g/l) (32 g/l) (125 g/l) (117 g/l) 4

Holm (1999)/[27] Ayoub (1999)/[4] Schmugge (2001)/[43] Yacobovitch (2001)/[54] Baca (2002)/[5] Anderson (2003)/[2] Sellami (2004)/[45] Vinet (2006)/[51] Taddio (2007)/[50] Raflores (2007)/[41] F/76 F/26 F/4 F/13 Hematuria, menorrhagia, rectorrhagia Hematoma,,, gum Gum,,, intramuscular hemorrhage macroscopic. menorrhagia no Lymphoma 1.5 12 (1 ) Miscarriage, preeclampsy (medical history) 0.12 U/mL SLE 3 40.3 (4 ) 0.2 U/L D acl: no Viral 2 27% <10% D acl: a-β2gp1: no SLE 2 IR 2.5 5% D acl: no Lupus-like syndrome 2.5 25.6 (2.3 ) 1% M/11 Epistaxis no SLE 2.5 28 (2.2 ) 1% F/3 M/23 F/50 M/13 M/38 gum Subdural Macroscopic, menorrhagia,, purpura LAHS diagnosed 15 yr earlier,, : 10 no viral 1.8 12 (1 ) 40% D Splenic infarction, pulmonary embolism Stroke Catheter-induced venous thrombosis SLE 1.5 24% 2% D SLE (20 yr earlier) SLE (3 yr earlier) SLE 3 IR 1.9 0.25 IU/mL D acl IgG: acl IgM: a-β2gp1: D acl IgG : 2 acl IgM: a-β2gp1: 1.5 acl: a-β2gp1: acl IgG: acl IgM: D 1.7 16.5 (1.3 ) 12% D D 1.5 15.6 (1.23 ) Primary APS 2 19.8 (1.3 ) 32% D acl: 0.20 IU/mL : 4 acl IgG: 4 (68 g/l) (122 g/l) (92 g/l) (93 g/l) 5

Clauser (2007)/[12] Davey (2007)/[15] Chung (2008)/[11] M/68 after minor trauma no Drug (quinidine) 1.5 16.5 (1.2 ) 31% M/2 Bruising Viral 3.3 36.5 (2.9) 2 IU/dL (: 50-150) : 3 D D acl IgG: 1.3 M/34 no no no 1.5 15.2 (1.6 ) 29% D D Appert-Flory (2010)/[3] F/2 bruising no Viral 2.6 79.9 (6 ) <10% acl IgG: Abbreviations: a-β2gp1 = anti-β 2-glycoprotein1 antibodies, acl = anticardiolipin antibodies, APS = antiphospholipid syndrome, aptt = activated partial thromboplastin time, IR = international normalized ratio, = n-times the upper limit of the normal range, D = not documented, = ative, =, PR = present report, PT = prothrombin time, SLE = systemic lupus erythematosus, VDRL+/TPHA- = false-itive syphilis serology. 6